Sarcoma
Welcome,         Profile    Billing    Logout  
 515 Companies   302 Products   302 Products   167 Mechanisms of Action   1404 Trials   125634 News 


«12...14791480148114821483148414851486148714881489...15771578»
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial initiation date, Trial primary completion date, Checkpoint inhibition, Checkpoint block:  Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma (clinicaltrials.gov) -  May 3, 2018   
    P1,  N=24, Not yet recruiting, 
    Not yet recruiting --> Active, not recruiting | N=66 --> 35 Trial completion date: Apr 2025 --> Aug 2025 | Initiation date: Apr 2018 --> Aug 2018 | Trial primary completion date: Apr 2024 --> Aug 2024
  • ||||||||||  cyclophosphamide / Generic mfg., thalidomide / Generic mfg.
    Trial completion date, Trial primary completion date, Post-transplantation:  Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors (clinicaltrials.gov) -  May 2, 2018   
    P1,  N=12, Recruiting, 
    Trial primary completion date: Feb 2017 --> Feb 2019 Trial completion date: Feb 2021 --> Feb 2022 | Trial primary completion date: Feb 2018 --> Feb 2020
  • ||||||||||  Journal:  Locally advanced carcinosarcoma of the pancreas. (Pubmed Central) -  May 1, 2018   
    Given such rarity, definitive treatment guidelines are not well defined. We report a case of pancreatic carcinosarcoma diagnosed in our institution, review tumor clinicopathological characteristics, and describe our medical and surgical management strategy.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Trial completion date, Trial primary completion date, Stroma, Japan:  Regorafenib Post-marketing Surveillance in Japan (clinicaltrials.gov) -  May 1, 2018   
    P=N/A,  N=135, Recruiting, 
    We report a case of pancreatic carcinosarcoma diagnosed in our institution, review tumor clinicopathological characteristics, and describe our medical and surgical management strategy. Trial completion date: Jun 2021 --> Jan 2021 | Trial primary completion date: Jun 2021 --> Jan 2021
  • ||||||||||  Bavencio (avelumab) / EMD Serono
    New P2 trial:  Paclitaxel-Avelumab for Angiosarcoma (clinicaltrials.gov) -  Apr 30, 2018   
    P2,  N=32, Not yet recruiting, 
  • ||||||||||  Tecelra (afamitresgene autoleucel) / Adaptimmune
    Enrollment change, Pan tumor:  MAGE-A4? (clinicaltrials.gov) -  Apr 30, 2018   
    P1,  N=42, Recruiting, 
    Trial completion date: Jun 2021 --> Jan 2021 | Trial primary completion date: Jun 2021 --> Jan 2021 N=32 --> 42
  • ||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
    Enrollment open, Myeloid-derived suppressor cells:  Dendritic Cell Vaccine for Children and Adults With Sarcoma (clinicaltrials.gov) -  Apr 26, 2018   
    P1,  N=56, Recruiting, 
    Further comparative studies examining vascularized grafts vs nonvascularized grafts or metallic cage constructs will be important in choosing the best reconstructive strategy. Suspended --> Recruiting
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD)
    New P2 trial, Epigenetic controller:  Vorinostat (SAHA) in Uterine Sarcoma (clinicaltrials.gov) -  Apr 25, 2018   
    P2,  N=8, Recruiting, 
  • ||||||||||  crenolanib besylate (ARO-002) / AROG, Sutent (sunitinib) / Pfizer
    Journal, IO biomarker:  Succinate dehydrogenase deficiency in a PDGFRA mutated GIST. (Pubmed Central) -  Apr 24, 2018   
    This is the first reported case of a PDGFRA mutant GIST exhibiting SDH-deficiency. A brief discussion of the relevant GIST literature is included.
  • ||||||||||  Enrollment open, Combination therapy:  FAZA PET/MRI Sarcoma (clinicaltrials.gov) -  Apr 24, 2018   
    P=N/A,  N=14, Recruiting, 
    Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Trial completion, Trial primary completion date, Metastases:  Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy (clinicaltrials.gov) -  Apr 23, 2018   
    P2/3,  N=37, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Sep 2018 --> Dec 2017
  • ||||||||||  imatinib / Generic mfg.
    Trial completion date, Trial primary completion date:  Basket 1: Imatinib in Patients With Desmoid Tumor and Chondrosarcoma (clinicaltrials.gov) -  Apr 19, 2018   
    P2,  N=35, Active, not recruiting, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Apr 2018 --> Dec 2019 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
  • ||||||||||  Ixempra (ixabepilone) - Otsuka, R / Pharm
    Trial completion:  Ixabepilone in Treating Patients With Recurrent or Persistent Uterine Cancer (clinicaltrials.gov) -  Apr 19, 2018   
    P2,  N=42, Completed, 
    Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 Active, not recruiting --> Completed
  • ||||||||||  carotuximab IV (ENV-105) / Kairos Pharma
    Trial completion date, Trial primary completion date, Metastases:  TAPPAS: Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma (clinicaltrials.gov) -  Apr 19, 2018   
    P3,  N=124, Recruiting, 
    Trial completion date: Dec 2017 --> Dec 2020 | Trial primary completion date: Dec 2017 --> Dec 2020 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
  • ||||||||||  Review, Journal:  Management of Sarcoma Metastases to the Lung. (Pubmed Central) -  Apr 18, 2018   
    With advancing surgical technique and adjuvant therapies, patients with high or recurrent tumor burden are increasingly afforded disease control and potential cure. In this review, the prognostic characteristics of pulmonary metastases from sarcoma, preoperative evaluation, operative technique, long-term outcomes, and management of complex patients are highlighted.
  • ||||||||||  Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma
    Review, Journal:  Liposarcoma: Multimodality Management and Future Targeted Therapies. (Pubmed Central) -  Apr 18, 2018   
    The groups differ in chemosensitivity, so adjuvant chemotherapy is selectively used in histologies with metastatic potential but not in the resistant subtype dedifferentiated liposarcoma. Improved understanding of the genetic aberrations that lead to liposarcoma initiation is allowing for the rapid development of targeted therapies for liposarcoma.
  • ||||||||||  Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
    Trial primary completion date, Metastases:  Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer (clinicaltrials.gov) -  Apr 18, 2018   
    P2,  N=72, Suspended, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial primary completion date: Dec 2017 --> Mar 2019